Akari Therapeutics Partners with WuXi XDC on ADCs Akari Therapeutics' Apr 6, 2026 ADC tie-up with WuXi XDC could accelerate preclinical timelines as the ADC market is projected at ~13.8% CAGR to 2030 (Grand View Research, 2024).

Akari Therapeutics Partners with WuXi XDC on ADCs: Akari Therapeutics' Apr 6, 2026 ADC tie-up with WuXi XDC could accelerate preclinical timelines as the ADC market is projected at ~13.8% CAGR to 2030 (Grand View… 👈 Read full analysis #AkariTherapeutics #WuXiXDC #ADCs #Biotechnology #Pharmaceuticals

WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform SHANGHAI, Feb. 27, 2026 /PRNewswire/ — WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform. Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs. This collaboration marks the establishment of a robust strategic partnership aimed at accelerating the development of next-generation ADCs by synergistically combining WuXi […]

WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform #WuXiXDC #EarendilLabs #Biotech #Collaboration #ADC